IP2Revenues LLC (IP2R), an Intellectual Property Commercialization & Licensing company, has signed a contract with the Fraunhofer USA Center for Molecular Biotechnology (FhCMB) to expedite commercialization of a proprietary technology developed by Fraunhofer.

"We're very excited about this partnership," said Dr. Kewal K. Likhyani, a former director of Licensing & Joint-Ventures and Patent Fellow at DuPont / INVISTA and current president of IP2R. "Our initial focus will be on Fraunhofer's virus-induced gene silencing technology which significantly promotes high-yield plant growth. Commercializing or licensing the technology through collaborations will allow us to get to market much faster."

The Fraunhofer USA Center for Molecular Biotechnology (FhCMB) is a not-for-profit, contract research organization focused on developing and applying plant science and other core platform technologies for the production of valuable proteins.

"Our transient gene expression technology," said Barry Marrs, executive director of FhCMB, "allows us to provide exceptional protein yields in a very short time. Our hope is that by working in conjunction with IP2R, a firm dedicated to rapidly bringing inventions to market, we can take better advantage of what the technology has to offer.